Regrese osteolytického loziska u pacienta s mnohocetným myelomem léceného klodronátem po uspesné terapii rezimem s bortezomibem
[Regression of an osteolytic lesion in a patient with multiple myeloma treated with clodronate after a successful therapy with bortezomib-based regimen]
Language Czech Country Czech Republic Media print
Document type Case Reports, Journal Article
PubMed
21717791
- MeSH
- Bortezomib MeSH
- Clodronic Acid therapeutic use MeSH
- Femur diagnostic imaging MeSH
- Remission Induction MeSH
- Bone Density Conservation Agents therapeutic use MeSH
- Boronic Acids administration & dosage MeSH
- Humans MeSH
- Multiple Myeloma complications diagnostic imaging drug therapy pathology MeSH
- Osteolysis complications diagnostic imaging drug therapy MeSH
- Antineoplastic Agents administration & dosage MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Pyrazines administration & dosage MeSH
- Radiography MeSH
- Recurrence MeSH
- Aged MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Bortezomib MeSH
- Clodronic Acid MeSH
- Bone Density Conservation Agents MeSH
- Boronic Acids MeSH
- Antineoplastic Agents MeSH
- Pyrazines MeSH
BACKGROUNDS: Osteolytic lesions are a common manifestation of multiple myeloma, though their healing is rare in these patients. Generally, during a complete remission, lesions only stop progressing; radiologically evident recalcification is exceptional. CASE: Herein we report a case of a male patient born in 1941 and diagnosed in 2005 with IgA multiple myeloma presenting with multiple osteolytic bone lesions. Administration of 4 cycles of VAD chemotherapy (vincristine, adriamycin, dexamethasone) with subsequent autologous peripheral blood stem cell transplantation and maintenance treatment with interferon alpha had resulted into a very good partial remission. In 2009, the disease relapsed with enlargement of osteolytic lesions evident on skiagrams. The largest lesion, reaching 24 x 10 mm in size, was located in the left femur. A complete remission of the disease was achieved with CVD senior regimen (cyclophosphamide, bortezomib, dexamethasone, 8 cycles in total). Bisphosphonates (zoledronate, ibandronate and, from 2007, clodronate) were administered as a long-term supportive therapy. A one-year follow-up skiagram of the left femur revealed over 50% regression of the osteolytic lesion (10 x 5 mm) documented in a set of pictures herein. CONCLUSION: A complete remission of the disease after an administration of bortezomib (Velcade)-based regimen in a long-term clodronate (Bonefos)-treated patient with relapsed multiple myeloma is radiographically apparent by clear healing signs of the osteolytic bone lesion.